在今年波澜壮阔的创新药行情中,谁是那稍纵即逝的烟火,谁又是那长期主义的明星?2025H1,乐普生物首次盈利,利润不少于2400万元,成为少数率先实现盈亏平衡的港股18A创新药企之一(含摘B企业),获得长期主义的能力,造血能力+研发能力+BD能力将互相强化,强者恒强。今年,乐普生物多个早期分子实现BD出海,验证自有技术平台价值,成为少数实现PD-1+ADC+多抗闭环布局的国内创新药企之一,PD-1+...
Source Link在今年波澜壮阔的创新药行情中,谁是那稍纵即逝的烟火,谁又是那长期主义的明星?2025H1,乐普生物首次盈利,利润不少于2400万元,成为少数率先实现盈亏平衡的港股18A创新药企之一(含摘B企业),获得长期主义的能力,造血能力+研发能力+BD能力将互相强化,强者恒强。今年,乐普生物多个早期分子实现BD出海,验证自有技术平台价值,成为少数实现PD-1+ADC+多抗闭环布局的国内创新药企之一,PD-1+...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.